Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer

FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer

New Capabilities

First cancer drug cleared based on a blood-detected resistance mutation, despite an advisory panel's 6-3 rejection

Today: News of first ctDNA-guided approval spreads

Overview

Updated 1 hour ago

The Food and Drug Administration (FDA) approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with a hormone-driven form of metastatic breast cancer that carries an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation detected in blood before scans show the disease has progressed.

The approval came despite a 6-3 vote against the drug by the FDA's own advisory panel in April. The agency also authorized Guardant Health's blood test, Guardant360 CDx, as a companion diagnostic to identify eligible patients. Whether early switching extends overall survival remains unproven; confirmatory trials are running.

The change: doctors can switch therapy as soon as the ESR1 resistance mutation shows up in a blood test. Circulating tumor DNA (ctDNA) is the genetic material tumors shed into blood, and it can reveal resistance before scans show growth. For patients, that can mean fewer rounds of chemotherapy and more time before the disease advances.

Why it matters

For women with ESR1-mutated metastatic breast cancer, a new pill delays disease progression a median of 6.8 months beyond standard care.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower Connections

Key Indicators

16 vs 9.2 months
Median PFS: Etcamah arm vs control
Patients switched to Etcamah lived a median 16 months without progression versus 9.2 months continuing aromatase inhibitor therapy.
6-3
April advisory committee vote against approval
ODAC said available data did not show a meaningful benefit; the FDA approved anyway.
~40%
Patients acquiring ESR1 mutations after aromatase inhibitor therapy
Fewer than 5% of patients have the mutation at metastatic diagnosis; nearly 40% develop it after progression on an aromatase inhibitor.
HR 0.44
Hazard ratio for disease progression or death
A 56% lower risk of progression or death for patients switched to Etcamah.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

AM
Angelo de Claro, M.D.
Director, FDA Oncology Center of Excellence
Led the FDA review that granted accelerated approval

Organizations Involved

U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted accelerated approval to Etcamah on September 4, 2026

The federal agency that approves new drugs and medical devices in the United States.
AstraZeneca
AstraZeneca
Pharmaceutical company
Markets Etcamah (camizestrant) after securing FDA accelerated approval

Anglo-Swedish drugmaker that developed camizestrant, an oral estrogen receptor antagonist.
Oncologic Drugs Advisory Committee (ODAC)
Oncologic Drugs Advisory Committee (ODAC)
FDA advisory committee
Voted 6-3 against camizestrant in April 2026; FDA overruled

Independent panel of cancer experts that advises the FDA on oncology drug applications.
Guardant Health
Guardant Health
Precision oncology company
Manufacturer of the Guardant360 CDx companion diagnostic approved with Etcamah

Company whose blood test was approved to identify ESR1-mutant patients for Etcamah.

Timeline

2021 September 2026

6 events Latest: Today
Tap a bar to jump to that date

  1. News of first ctDNA-guided approval spreads

    Today Announcement

    Medical and mainstream outlets report Etcamah as the first blood-test-selected cancer therapy.

  2. FDA grants Etcamah accelerated approval

    Regulatory Approval

    Camizestrant approved with a CDK4/6 inhibitor; Guardant360 CDx authorized as companion diagnostic.

  3. Updated survival data presented at ASCO

    Presentation

    SERENA-6 follow-up shows improved second progression-free survival at ASCO 2026.

  4. FDA delays decision to review ctDNA analyses

    Regulatory

    Agency postpones ruling to examine supplemental ctDNA clearance data.

  5. FDA panel votes 6-3 against camizestrant

    Regulatory

    ODAC says available data fail to show a clinically meaningful benefit.

  6. SERENA-6 trial launches

    Clinical Trial

    Phase 3 trial tests early switch to camizestrant when ESR1 mutations appear in blood.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1998

Trastuzumab (Herceptin) with HER2 testing (1998)

The FDA approved trastuzumab for HER2-positive metastatic breast cancer, alongside a diagnostic test to identify patients whose tumors overexpressed the HER2 protein. It was one of the first targeted breast cancer therapies tied to a companion diagnostic.

Then

Herceptin became a standard of care for HER2-positive patients and transformed that subtype's outlook.

Now

Established the companion diagnostic model: a drug approved together with a test that selects the right patients.

Why this matters now

Etcamah follows the same model, pairing a targeted drug with the Guardant360 CDx blood test to find ESR1-mutant patients.

November 2015

Osimertinib (Tagrisso) for EGFR T790M (2015)

The FDA approved osimertinib for non-small cell lung cancer patients with the EGFR T790M resistance mutation, which develops during earlier EGFR inhibitor therapy. The mutation could be detected in blood or tissue before the drug was prescribed.

Then

Osimertinib became a standard second-line treatment and was later moved to first-line use.

Now

Showed how targeting an acquired resistance mutation can become a front-line therapy, expanding the eligible patient population.

Why this matters now

A recent precedent for a drug approved for a resistance mutation that later shifted to earlier lines, which Etcamah may also attempt.

2010s-2020s

FDA accelerated approvals and Project Confirm (2010s-2020s)

The FDA's accelerated approval program allows early approval based on surrogate endpoints, with confirmatory trials required afterward. Under Project Confirm, the agency tracks these trials, and drugs whose confirmatory studies fail can be withdrawn.

Then

Several drugs have been withdrawn or had their indications narrowed when confirmatory trials disappointed.

Now

Established a template where approvals are provisional: continued marketing depends on demonstrated real-world or trial benefit.

Why this matters now

Eetcamah's approval carries the same provisional condition; SERENA-6's pending overall survival data will determine whether it stays on the market.

Sources

(10)
+4
U.S. Food and Drug Administration The ASCO Post CancerNetwork Healio UPI OncoDaily Pharma Now Nova Pharma News Rojadigital U.S. Food and Drug Administration